根据国家统计局数据显示：2025年6月中国化学药品原药产量为33.3万吨，同比增长5.4%；2025年1-6月 中国化学药品原药累计产量为192万吨，累计增长4.8%。 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市企业：恒瑞医药（600276）,华东医药（000963）,丽珠集团（000513）,白云山（600332）,华北制药 （600812）,海正药业（600267）,复星医药（600196）,科伦药业（002422）,恩华药业（002262）,仙琚 制药（002332） 相关报告：智研咨询发布的《2025-2031年中国化学药品行业市场供需态势及未来趋势研判报告》 数据来源：国家统计局，智研咨询整理 ...

Group 1 - The core viewpoint emphasizes the significant increase in foreign investment in research and development (R&D) in China, with R&D expenditure growing over 86% and the number of effective invention patents increasing by 336% over the past decade [1] - Foreign-funded enterprises in China are seen as crucial to the country's technological innovation system, attracting high-end talent and advanced technologies, which contribute to economic restructuring and industrial upgrading [1][2] - The report highlights that foreign enterprises are increasingly integrating into China's economic system, benefiting from the country's large consumer market and complete manufacturing supply chain [2][3] Group 2 - The Chinese economy is undergoing a transformation focused on quality over quantity, with foreign investment in high-end services and manufacturing continuing to grow despite global economic challenges [3] - Specific sectors such as e-commerce services, aerospace manufacturing, and pharmaceuticals have seen substantial foreign investment growth, indicating the increasing importance of the Chinese market [3] - The shift of foreign enterprises from market-driven to innovation-driven models in China enhances their competitiveness in both domestic and global markets [3][4]